Trial Profile

Phase 1 Trial of Intralesional Immunotherapy With IFx-Hu2.0 Vaccine in Patients With Advanced Non-melanoma Skin Cancers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IFx 2.0 (Primary) ; IFx 2.0 (Primary)
Indications Merkel cell carcinoma; Skin cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors TuHURA Biosciences

Most Recent Events

05 Aug 2024 Planned End Date changed from 30 Dec 2023 to 31 Aug 2024.
04 Jun 2024 Primary endpoint has been met (feasibility of repeated IT administrations of the investigational agent) , according to Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com